Skip to Content
Merck
  • Cholesterol-induced non-alcoholic fatty liver disease and atherosclerosis aggravated by systemic inflammation.

Cholesterol-induced non-alcoholic fatty liver disease and atherosclerosis aggravated by systemic inflammation.

PloS one (2014-06-06)
Eung Ju Kim, Baek-hui Kim, Hong Seog Seo, Yong Jik Lee, Hyun Hee Kim, Hyun-Hwa Son, Man Ho Choi
ABSTRACT

Although triglyceride accumulation in the liver causes non-alcoholic fatty liver disease (NAFLD), hypercholesterolemia is also a main cause of NAFLD as well as atherosclerosis. However, NAFLD and atherosclerosis have not been investigated simultaneously in animal models fed a high-cholesterol diet. Moreover, it is unclear whether systemic inflammation can exacerbate both pathologies in the same model. Accordingly, this study investigated the effect of additional systemic inflammation on NAFLD and atherosclerosis induced by cholesterol overload in wild animals. New Zealand white rabbits were divided into 4 groups: groups I (control) and II received normal chow, and groups III and IV received a 1% cholesterol diet. To induce inflammation via toll-like receptor (TLR)-4 signaling, groups II and IV received subcutaneous injections of 0.5 mL of 1% carrageenan every 3 weeks. After 3 months, total cholesterol markedly increased in groups III and IV, and the serum expressions of systemic inflammatory markers were elevated in the groups II-IV. Early NAFLD lesions (e.g., mild fatty changes in the liver with sporadic fibrosis) and atherosclerosis (e.g., intimal hyperplasia composed of foam cells) were observed in both the liver and aorta specimens from group III, and advanced lesions were observed in group IV. The expressions of inflammatory cellular receptors, TLR-2 and TLR-4, in the aorta gradually increased from group I to IV but were similar in the liver in groups II-IV. Cholesteryl ester (CE) levels were higher in group IV than in group III, although the difference was not significant. CE levels in the aorta were similar between groups III and IV. Systemic inflammation can simultaneously exacerbate existing early lesions due to cholesterol overload in both the liver and aorta of rabbits. However, the cellular response of inflammatory receptors and expression of cholesterol metabolites differ between these organs.

MATERIALS
Product Number
Brand
Product Description

Supelco
Cholesterol, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Cholesterol solution, certified reference material, 10 mg/mL in chloroform
Supelco
N-Methyl-bis(trifluoroacetamide), for GC derivatization, LiChropur, ≥99.0% (GC)
Sigma-Aldrich
Ammonium iodide, 99.999% trace metals basis
Sigma-Aldrich
1,4-Dithioerythritol, ≥99.0% (RT), BioUltra
Sigma-Aldrich
Cholesterol, tested according to Ph. Eur.
Sigma-Aldrich
1,4-Dithioerythritol, ≥99.0%
Sigma-Aldrich
Cholesterol, Sigma Grade, ≥99%
Sigma-Aldrich
Cholesterol, from sheep wool, ≥92.5% (GC), powder
Sigma-Aldrich
1,4-Dithioerythritol, BioReagent, for molecular biology, ≥99.0%
Sigma-Aldrich
Cholesterol, powder, BioReagent, suitable for cell culture, ≥99%
Supelco
N-Methyl-bis(trifluoroacetamide), for GC derivatization, LiChropur, ≥97.0% (GC)
Sigma-Aldrich
1,4-Dithioerythritol, BioXtra, ≥99.0%
SAFC
Cholesterol, from sheep wool, Controlled origin, meets USP/NF testing specifications
SAFC
Cholesterol, Plant-Derived, SyntheChol®
Sigma-Aldrich
Deuterium, 99.9 atom % D
Sigma-Aldrich
Deuterium, 99.96 atom % D
Sigma-Aldrich
Deuterium hydride, extent of labeling: 96 mol% DH, 98 atom % D
Supelco
N-Methyl-N-(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane, for GC derivatization, LiChropur
Supelco
N-Methyl-N-(trimethylsilyl)trifluoroacetamide, for GC derivatization, LiChropur, ≥98.5%
Supelco
N-Methyl-N-(trimethylsilyl)trifluoroacetamide, synthesis grade
Sigma-Aldrich
Deuterium, 99.8 atom % D
Supelco
N-Methyl-N-(trimethylsilyl)trifluoroacetamide, BioReagent, for silylations, LiChropur